Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

RAD Presentation July 2026

Thursday, July 23, 2026 1 min read
Key Takeaway: Radiopharm Theranostics has reported positive outcomes from its Phase 2b trial of RAD 101, aimed at diagnosing brain metastases. Additionally, the company has initiated a Phase 1/2a clinical study for BetaBart (RV-01) and received IND approval from the US FDA to start therapeutic studies targeting B7H3. These developments highlight the company's progress in advancing its clinical programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive Phase 2b trial results for RAD 101.
  • First patient dosed in Phase 1/2a study of BetaBart.
  • IND approval received from the US FDA for Betabart.

Full Press Release Details

• Investor Presentations
• July 23, 2026
Loading Viewer…

More Announcements & Updates

• Announcements
• November 22, 2023
• Announcements
• January 6, 2023
• Announcements
• August 27, 2024
• Announcements
• March 6, 2023

Radiopharm Theranostics Announces Positive Phase 2b Trial Resultsof RAD 101 for Diagnosis of Brain Metastases

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

• Radiopharm Theranostics Announces Positive Phase 2b Trial Resultsof RAD 101 for Diagnosis of Brain Metastases
• RAD Presentation July 2026
• Zacks Small-Cap Research 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What were the results of the Phase 2b trial for RAD 101?

The Phase 2b trial for RAD 101 yielded positive results for diagnosing brain metastases.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic candidate currently in a Phase 1/2a clinical study.

What FDA approval did Radiopharm receive?

Radiopharm received IND approval from the US FDA to initiate a Phase I study targeting B7H3.

When is the RAD presentation scheduled?

The RAD presentation is scheduled for July 23, 2026.

Tags: RADX Viatris Investor Conferences Healthcare Phase 2b trial BetaBart clinical study FDA approval
Last updated: Jul 23, 2026